Pathogens
A breakthrough in SARS-CoV-2 personal protection
Pathogen Inactivation
  • Nanowave technology has now been tested with the COVID-19 virus, Staphylococcus, and Bacteriophage PhiX174. The inactivation rates for a Nanowave Air device operating at 300 LPM is as follows:
  • Nanowave technology has now been tested in enough experiments with enough different types of pathogens, including over 120 experiments against the Covid-19 virus itself, that inactivation rates for additional airborne viruses and bacteria have been developed. The below inactivation rates were developed using Dynamics’ proprietary data, historical public data, and generally accepted scientific methods.
Tested against the COVID-19 virus
Nanowave technology has been successfully tested against SARS-CoV-2 at multiple labs in the NIAID Biodefense Laboratory Network. Tested devices exceeded maximum airflow speeds of the labs and the virus detection capability of those tests.
  • Tested at the Galveston National Laboratory (a National Laboratory in the NIAID Biodefense Laboratory Network)1: Letter 1. Letter 2.
  • Tested at Colorado State University (a Regional Laboratory in the NIAID Biodefense Laboratory Network)1: Letter 1.
  • Nanowave technology was also tested with ΦX174 bacteriophage, a 50 nanometer DNA virus, at 30 LPM which is a standard test for mechanical filters at Nelson Labs, where it achieved an average inactivation of 99.99907%. Nanowave technology was also tested at Nelson Labs at 150 LPM against the same bacteriophage and achieved 99.6%1: Letter 1. Letter 2.
  • Nanowave technology was also tested with Staphylococcus aureus, a bacteria, at 150 LPM at Nelson Labs, where it achieved an average inactivation of 99.9977%1: Letter 1.
  • Multiple third-party experts verified the performance of the Nanowave Air. An example of a third-party verification can be found here: Letter 1.

1The technology behind the Nanowave Air was tested, not the Nanowave Air itself and the tests were performed at different airflow and power settings than the airflow and power settings in the Nanowave Air device. The studies, however, were used to determine the Nanowave Air performance and this performance was verified by multiple third parties based on the data from the studies. The COVID-19 virus and the Nanowave technology is new and Dynamics currently intends to continue to perform studies with the Nanowave Technology against the COVID-19 virus. Additionally, Dynamics is utilizing and relying on third party materials, such as third party UV-C materials, and is relying on performance attributes from these third party material supplier. New studies may improve the understanding of the Nanowave technology against the COVID-19 virus and the performance data of Nanowave Air may change if new understandings are properly verified.